RBC Capital Sticks to Their Buy Rating for Flowserve (FLS)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
According to TipRanks, Dray is a 5-star analyst with an average return of 14.3% and a 64.93% success rate. Dray covers the Industrials sector, focusing on stocks such as Carrier Global, Emerson Electric Company, and Trane Technologies.
In addition to RBC Capital, Flowserve also received a Buy from Citi's Andrew Kaplowitz in a report issued on July 14. However, on July 8, Goldman Sachs maintained a Hold rating on Flowserve (NYSE: FLS).
Based on Flowserve's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.14 billion and a net profit of $73.91 million. In comparison, last year the company earned a revenue of $1.09 billion and had a net profit of $74.22 million
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
23 minutes ago
- Business Insider
Jarden Keeps Their Sell Rating on Mineral Resources Limited (MALRF)
Jarden analyst Ben Lyons maintained a Sell rating on Mineral Resources Limited on July 31 and set a price target of A$14.60. The company's shares closed last Tuesday at $17.30. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Lyons is a 4-star analyst with an average return of 8.9% and a 68.35% success rate. Lyons covers the Basic Materials sector, focusing on stocks such as Mineral Resources Limited, Greatland Resources, and Northern Star Resources Ltd. In addition to Jarden, Mineral Resources Limited also received a Sell from Macquarie's Robert Stein in a report issued on August 1. However, yesterday, Citi maintained a Hold rating on Mineral Resources Limited (Other OTC: MALRF).
Yahoo
an hour ago
- Yahoo
Pfizer (PFE) Reports Earnings Tomorrow: What To Expect
Global pharmaceutical company Pfizer (NYSE:PFE) will be announcing earnings results this Tuesday before market open. Here's what to look for. Pfizer missed analysts' revenue expectations by 1.6% last quarter, reporting revenues of $13.72 billion, down 7.8% year on year. It was a mixed quarter for the company, with a solid beat of analysts' organic revenue estimates but a miss of analysts' full-year EPS guidance estimates. Is Pfizer a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Pfizer's revenue to grow 2.2% year on year to $13.58 billion, in line with the 2.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.57 per share. Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 6 downward revisions over the last 30 days (we track 11 analysts). Pfizer has missed Wall Street's revenue estimates three times over the last two years. Looking at Pfizer's peers in the branded pharmaceuticals segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Bristol-Myers Squibb posted flat year-on-year revenue, beating analysts' expectations by 7.8%, and Merck reported a revenue decline of 1.9%, falling short of estimates by 1.1%. Bristol-Myers Squibb traded down 3.9% following the results while Merck was also down 2.7%. Read our full analysis of Bristol-Myers Squibb's results here and Merck's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the branded pharmaceuticals stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Pfizer is down 6.8% during the same time and is heading into earnings with an average analyst price target of $28.67 (compared to the current share price of $23.53). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
an hour ago
- Yahoo
Earnings To Watch: Alight (ALIT) Reports Q2 Results Tomorrow
Human capital management provider Alight (NYSE:ALIT) will be reporting earnings this Tuesday morning. Here's what investors should know. Alight beat analysts' revenue expectations by 1.2% last quarter, reporting revenues of $548 million, down 2% year on year. It was a strong quarter for the company, with an impressive beat of analysts' EPS guidance for next quarter estimates and full-year revenue guidance meeting analysts' expectations. Is Alight a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Alight's revenue to decline 2.4% year on year to $525 million, improving from the 4.1% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.10 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Alight has missed Wall Street's revenue estimates five times over the last two years. Looking at Alight's peers in the professional staffing & hr solutions segment, some have already reported their Q2 results, giving us a hint as to what we can expect. ManpowerGroup posted flat year-on-year revenue, beating analysts' expectations by 3.6%, and Robert Half reported a revenue decline of 7%, topping estimates by 1.1%. ManpowerGroup's stock price was unchanged after the resultswhile Robert Half was down 6.1%. Read our full analysis of ManpowerGroup's results here and Robert Half's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the professional staffing & hr solutions stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.4% on average over the last month. Alight is down 14% during the same time and is heading into earnings with an average analyst price target of $9.57 (compared to the current share price of $5.10). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
